Medical News Today -- Pfizer announced that Xalatan 0.005% (latanoprost) has been approved by the European Commission for reduction of elevated intraocular pressure (IOP) in the treatment of paediatric patients with elevated intraocular pressure and paediatric glaucoma. Latanoprost is the first prostaglandin analogue to complete safety and efficacy trials in the paediatric population and be indicated for use in patients aged 18 years or younger in Europe.
